Legend Biotech (LEGN) Gains from Sales and Divestitures (2021 - 2025)
Legend Biotech (LEGN) reported Gains from Sales and Divestitures of $250000.0 for Q2 2025, up 12400.0% on a YoY basis from N/an in Q2 2024, and up 371.7% quarter-over-quarter from $53000.0 in Q1 2025.
Legend Biotech (LEGN) Gains from Sales and Divestitures (2021 - 2025) Analysis & Trends
Legend Biotech has reported Gains from Sales and Divestitures for 5 years, with the latest figure at $250000.0 in Q2 2025.
- For the quarter ending Q2 2025, Gains from Sales and Divestitures rose 12400.0% year-over-year to $250000.0; the trailing twelve-month figure through Jun 2025 stood at $250000.0 (up 12400.0% YoY), and the FY2022 full-year result was $481000.0, down 50.62% from the prior year.
- Gains from Sales and Divestitures for Q2 2025 stood at $250000.0, up from $53000.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $481000.0 in Q4 2022, with the low at $2000.0 in Q1 2024.
- Historically, Gains from Sales and Divestitures has averaged $102307.7 across 5 years, with a median of $53000.0 in 2025.
- Annual changes were most pronounced in 2024 — Gains from Sales and Divestitures tumbled 99.1% — and 2025, when it surged 12400.0%.
- Legend Biotech's Gains from Sales and Divestitures stood at $54000.0 in 2021, then soared by 790.74% to $481000.0 in 2022, then slumped by 53.64% to $223000.0 in 2023, then plunged by 99.1% to $2000.0 in 2024, then surged by 12400.0% to $250000.0 in 2025.
- The last three Gains from Sales and Divestitures figures came in at $250000.0 (Q2 2025), $53000.0 (Q1 2025), and $2000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 250,000.00 |
| Jun 30, 2025 | 250,000.00 |
| Mar 31, 2025 | 53,000.00 |
| Mar 31, 2025 | 53,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Sep 30, 2023 | 223,000.00 |
| Sep 30, 2023 | 223,000.00 |
| Jun 30, 2023 | 141,000.00 |
| Jun 30, 2023 | 141,000.00 |
| Mar 31, 2023 | 75,000.00 |
| Mar 31, 2023 | 75,000.00 |
| Dec 31, 2022 | 481,000.00 |
| Dec 31, 2022 | 481,000.00 |
| Sep 30, 2022 | 8,000.00 |
| Sep 30, 2022 | 8,000.00 |